Iris Vogelaar

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. ncbi Screening for colorectal cancer: which test can we afford?
    I Lansdorp-Vogelaar
    Department of Public Health, Erasmus MC, University Medical Center Rotterdam, The Netherlands
    Z Gastroenterol 46:S38-40. 2008
  2. ncbi Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening
    Iris Lansdorp-Vogelaar
    Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    J Natl Cancer Inst 101:1412-22. 2009
  3. ncbi European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition--Introduction
    I Lansdorp-Vogelaar
    Department of Public Health, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands
    Endoscopy 44:SE15-30. 2012
  4. ncbi Contribution of screening and survival differences to racial disparities in colorectal cancer rates
    Iris Lansdorp-Vogelaar
    Department of Public Health, Erasmus MC, Rotterdam, The Netherlands
    Cancer Epidemiol Biomarkers Prev 21:728-36. 2012
  5. ncbi Cost-effectiveness of colorectal cancer screening
    Iris Lansdorp-Vogelaar
    Department of Public Health, Erasmus MC, University Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Epidemiol Rev 33:88-100. 2011
  6. ncbi Cost-effectiveness of colorectal cancer screening--an overview
    Iris Lansdorp-Vogelaar
    Department of Public Health, Erasmus MC, University Medical Center, P O Box 2040, 3000 CA Rotterdam, The Netherlands
    Best Pract Res Clin Anaesthesiol 24:439-49. 2010
  7. ncbi Stool DNA testing to screen for colorectal cancer in the Medicare population: a cost-effectiveness analysis
    Iris Lansdorp-Vogelaar
    Erasmus Medical Center, Rotterdam, The Netherlands
    Ann Intern Med 153:368-77. 2010
  8. ncbi Cost-effectiveness of colorectal cancer screening - an overview
    Iris Lansdorp-Vogelaar
    Department of Public Health, Erasmus MC, University Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Best Pract Res Clin Gastroenterol 24:439-49. 2010
  9. ncbi Individualizing colonoscopy screening by sex and race
    Iris Lansdorp-Vogelaar
    Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Gastrointest Endosc 70:96-108, 108.e1-24. 2009
  10. ncbi A novel hypothesis on the sensitivity of the fecal occult blood test: Results of a joint analysis of 3 randomized controlled trials
    Iris Lansdorp-Vogelaar
    Department of Public Health, Erasmus MC, University Medical Center Rotterdam, The Netherlands
    Cancer 115:2410-9. 2009

Detail Information

Publications12

  1. ncbi Screening for colorectal cancer: which test can we afford?
    I Lansdorp-Vogelaar
    Department of Public Health, Erasmus MC, University Medical Center Rotterdam, The Netherlands
    Z Gastroenterol 46:S38-40. 2008
  2. ncbi Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening
    Iris Lansdorp-Vogelaar
    Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    J Natl Cancer Inst 101:1412-22. 2009
    ..We examined whether colorectal cancer screening would become cost saving with the widespread use of the newer, more expensive chemotherapies...
  3. ncbi European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition--Introduction
    I Lansdorp-Vogelaar
    Department of Public Health, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands
    Endoscopy 44:SE15-30. 2012
    ....
  4. ncbi Contribution of screening and survival differences to racial disparities in colorectal cancer rates
    Iris Lansdorp-Vogelaar
    Department of Public Health, Erasmus MC, Rotterdam, The Netherlands
    Cancer Epidemiol Biomarkers Prev 21:728-36. 2012
    ..We estimated how much of these disparities could be explained by differences in CRC screening and stage-specific relative CRC survival...
  5. ncbi Cost-effectiveness of colorectal cancer screening
    Iris Lansdorp-Vogelaar
    Department of Public Health, Erasmus MC, University Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Epidemiol Rev 33:88-100. 2011
    ..There was agreement among studies that the newly developed screening tests of stool DNA testing, computed tomographic colonography, and capsule endoscopy were not yet cost-effective compared with the established screening options...
  6. ncbi Cost-effectiveness of colorectal cancer screening--an overview
    Iris Lansdorp-Vogelaar
    Department of Public Health, Erasmus MC, University Medical Center, P O Box 2040, 3000 CA Rotterdam, The Netherlands
    Best Pract Res Clin Anaesthesiol 24:439-49. 2010
    ..There is consensus that the new technologies of stool DNA testing, computed tomographic colonography and capsule endoscopy are not yet cost-effective compared with the established CRC screening tests...
  7. ncbi Stool DNA testing to screen for colorectal cancer in the Medicare population: a cost-effectiveness analysis
    Iris Lansdorp-Vogelaar
    Erasmus Medical Center, Rotterdam, The Netherlands
    Ann Intern Med 153:368-77. 2010
    ..The Centers for Medicare & Medicaid Services considered whether to reimburse stool DNA testing for colorectal cancer screening among Medicare enrollees...
  8. ncbi Cost-effectiveness of colorectal cancer screening - an overview
    Iris Lansdorp-Vogelaar
    Department of Public Health, Erasmus MC, University Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Best Pract Res Clin Gastroenterol 24:439-49. 2010
    ..There is consensus that the new technologies of stool DNA testing, computed tomographic colonography and capsule endoscopy are not yet cost-effective compared with the established CRC screening tests...
  9. ncbi Individualizing colonoscopy screening by sex and race
    Iris Lansdorp-Vogelaar
    Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Gastrointest Endosc 70:96-108, 108.e1-24. 2009
    ..There is increasing discussion whether colorectal cancer (CRC) screening guidelines should be individualized by sex and race...
  10. ncbi A novel hypothesis on the sensitivity of the fecal occult blood test: Results of a joint analysis of 3 randomized controlled trials
    Iris Lansdorp-Vogelaar
    Department of Public Health, Erasmus MC, University Medical Center Rotterdam, The Netherlands
    Cancer 115:2410-9. 2009
    ..In addition to 2 usual hypotheses on the sensitivity of FOBT, we tested a novel hypothesis where sensitivity is linked to the stage of clinical diagnosis in the situation without screening...
  11. ncbi At what costs will screening with CT colonography be competitive? A cost-effectiveness approach
    Iris Lansdorp-Vogelaar
    Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Int J Cancer 124:1161-8. 2009
    ..Our estimate of 43% is considerably lower than previous estimates in literature, because previous studies only compared CTC screening to 10-yearly colonoscopy, where we compared to different intervals of colonoscopy screening...
  12. ncbi How much can current interventions reduce colorectal cancer mortality in the U.S.? Mortality projections for scenarios of risk-factor modification, screening, and treatment
    Iris Vogelaar
    Department of Public Health, Erasmus MC, University Medical Center Rotterdam, The Netherlands
    Cancer 107:1624-33. 2006
    ..This study assessed the potential reduction in CRC mortality that may be achieved through further dissemination of current interventions for risk-factor modification, screening, and treatment...